AI assistant
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2014
Jun 16, 2014
32254_dirs_2014-06-16_1f28267a-0ef3-4d9d-83bc-d2fc1ab893bd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: pSivida Corp. (PSDV)
CIK: 0001314102
Period of Report: 2014-06-12
Reporting Person: Freedman Lori (VP Corp. Affairs, GC and Sec)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-06-12 | Common Stock | M | 9600 | $1.81 | Acquired | 106023 | Direct |
| 2014-06-12 | Common Stock | S | 9600 | $4.02 | Disposed | 96423 | Direct |
| 2014-06-13 | Common Stock | M | 2100 | $1.81 | Acquired | 98523 | Direct |
| 2014-06-13 | Common Stock | S | 2100 | $4.01 | Disposed | 96423 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-06-12 | Stock Option (Right to Buy) | $1.81 | M | 9600 | Disposed | 2019-06-25 | Common Stock (9600) | Direct |
| 2014-06-13 | Srock Option (Right to Buy) | $1.81 | M | 2100 | Disposed | 2019-06-25 | Common Stock (2100) | Direct |
Footnotes
F1: Shares sold pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person with respect to the Common Stock of the Issuer.
F2: The option was granted on 06/25/2009 and vested in four equal annual installments beginning on the first anniversary of the date of grant.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.09. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.